melanocortin receptor is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
The compound binds several melanocortin receptor subtypes rather than a single target, with the strongest functional activity reported at MC4R and measurable activity at MC1R, MC3R and MC5R. MC4R populations are dense in hypothalamic nuclei that integrate energy balance, autonomic tone and reproductive behaviour, which is the anatomical basis for the proposed pro-desire effect. Because binding is not subtype-selective, pigmentary and vascular effects accompany central activity. Improving subtype selectivity is an active area of analogue design. Direct causal mapping from receptor occupancy to reported desire change in humans is not fully established.
After subcutaneous dosing, peak plasma concentrations appear within roughly one hour, and elimination is fast, with a half-life on the order of a few hours. Degradation is mainly proteolytic, and at least one circulating fragment retains receptor activity, so parent-drug levels alone do not describe total exposure. Clearance does not depend heavily on hepatic cytochrome enzymes, which lowers the likelihood of common metabolic interaction routes. Data in renal or hepatic impairment are limited. Repeated dosing does not appear to produce marked accumulation given the short half-life.
Reported pharmacodynamic effects include transient rises in blood pressure and heart rate, flushing, nausea and headache, appearing soon after dosing and resolving within hours. These responses were dose-related in early studies and shaped the label's cardiovascular cautions and blood pressure monitoring advice. Gastrointestinal upset is the most frequent reason cited for discontinuation in trials. Whether the vascular signal attenuates with repeated use is not settled. Central effects on desire are described as emerging over weeks rather than immediately, which points to a cumulative rather than acute process.
Compared with the related compound melanotan II, PT-141 shows markedly weaker activation of receptors tied to pigmentation. This difference stems from subtle structural variations that alter affinity distribution across receptor subtypes. Investigators propose that such selectivity produces a different side effect profile in specific applications. However, downstream consequences of prolonged receptor activation remain uncertain in the literature. Published studies do not fully agree on the duration of signaling pathway activity and the mechanisms of desensitization.
From a pharmacokinetic standpoint, the peptide is usually delivered by injection because oral bioavailability is very low; proteases in the digestive tract degrade it rapidly. After subcutaneous administration, plasma concentrations reach a peak within roughly one hour. Its elimination half-life is relatively short, with most reports placing it in the range of a few hours. Nasal formulations have also been examined, though absorption varies widely between individuals. Metabolism proceeds mainly through peptidase cleavage, and the resulting products are excreted by the kidneys.
| Property | Value | Notes |
|---|---|---|
| Primary target | MC4R | Highest reported functional activity |
| Peak plasma time | About 1 hour | Subcutaneous administration |
| Elimination half-life | A few hours | Active fragment may extend effect |
| Main clearance route | Proteolytic degradation | Not cytochrome-dependent |
| Typical assay | LC-MS/MS | Plasma quantification |
Bremelanotide, developed under the code PT-141, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. Its structure is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a lactam bridge joining the aspartate and lysine side chains. The molecule has the formula C50H68N14O10 and a monoisotopic mass near 1025 daltons. It is commonly prepared as the acetate salt and appears as a white to off-white lyophilised powder in solid form. The free acid is the pharmacologically relevant species, while the counter-ion improves handling and dissolution.
Early research on PT-141 grew out of work on melanotan II, a related cyclic peptide studied for pigmentation. Investigators observed that centrally acting melanocortin agonists also influenced sexual behaviour in animal models, and the programme shifted toward that endpoint. A nasal formulation was evaluated in clinical trials but showed inconsistent absorption, and later studies used subcutaneous administration instead. Regulatory approval in the United States followed in 2019 for a defined population of premenopausal women with acquired, generalised hypoactive sexual desire disorder. That approval was specific to that group rather than a broad indication.
Bremelanotide acts as a non-selective agonist at melanocortin receptors, with reported activity at MC1R, MC3R, MC4R and MC5R. The proposed basis for its central effects is activation of MC4R populations in the hypothalamus, a region associated with appetite and reproductive signalling. Because the peptide carries a net positive charge and polar side chains, it does not cross biological membranes freely, which is one reason oral administration is not the standard route. Effects generally appear within an hour of parenteral administration and are described as centrally mediated rather than peripheral.
PT-141 is the original development code for bremelanotide, a synthetic peptide first studied as a potential tanning and sexual-response agent in the 1990s. Researchers at a small American biotechnology firm designed it as a shortened analogue of melanotan II, which itself came from work on alpha-melanocyte-stimulating hormone. Early screening focused on pigmentation, but behavioural observations in animal models redirected attention toward sexual motivation. That shift made PT-141 one of the first melanocortin compounds investigated specifically for effects on desire rather than on skin colour.
Clinical development proceeded through two routes of administration. An intranasal formulation advanced first, but variable absorption and tolerability problems led to a switch to subcutaneous injection. The United States Food and Drug Administration approved the subcutaneous product in 2019 for hypoactive sexual desire disorder in premenopausal women. Marketing rights subsequently changed hands, and commercial availability has fluctuated since approval. Use in men, in postmenopausal women, and in combination with other agents remains outside the approved label.
Outside the approved product, bremelanotide circulates as a research chemical sold by peptide vendors, often labelled PT-141. Such material is not manufactured under pharmaceutical quality standards, and independent testing has repeatedly found content that differs from the label. Analytical certificates supplied with a purchase are not strong evidence of purity because they are usually generated by the seller. Online discussion tends to blur the distinction between the approved drug and unregulated powder, which complicates interpretation of reported experiences.
Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
=== Protein radical formation === Glycyl radical enzyme activating enzymes (GRE-AEs) are radical SAM subset that can house a stable and catalytically essential glycyl radical in their active state. The underlying chemistry is considered to be the simplest in the radical SAM superfamily with H-atom abstraction by the 5'-dAdo radical being the product of the reaction. A few examples include:
Bush then issued a statement saying that while Trump was within his rights to call for recounts, he believed the election was "fundamentally fair" and that "its outcome is clear", and said he would offer Biden "my prayers for his success, and my pledge to help in any way I can", as he had for Trump and Obama.
China began using it in 1997, Guatemala in 1996, the Philippines in 1999, Thailand in 2003, Taiwan in 2005, and Vietnam first used this method in 2013. The Philippines abolished the death penalty in 2006, with their last execution being that of Alex Bartolome in January 2000. All seven executions made from 1999 to 2000 were carried out using lethal injection. Guatemalan law still allows for the death penalty and lethal injection is the sole method allowed, but none have been carried out since 2000 when the country televised the live double executions of Amílcar Cetino Pérez and Tomás Cerrate Hernández.
In fact, the variables were nearly too widespread to track, including: spontaneous fermentation, the type of vessels used, environmental conditions, and the apple varieties. Refinements came much later when cider became a commercial product and the process was better understood. However, since there is growing popularity in ciders, the production of speciality styles has begun to increase. Cider alcohol content varies from 1.2% to 8.5% ABV or more in traditional English ciders, and 2.5% to 12% in continental ciders. In UK law, it must contain at least 35% apple juice (fresh or from concentrate), although CAMRA (the Campaign for Real Ale) says that "real cider" must be at least 90% fresh apple juice. In the US, there is a 50% minimum. In France, cider must be made solely from apples. Perry is a similar product to cider made by fermenting pear juice. Cider can be distilled into fruit brandy. In the US and Canada, varieties of alcoholic cider are often called "hard cider" to distinguish it from non-alcoholic apple cider or "sweet cider", also made from apples at cider mills. In Canada, cider cannot contain less than 2.5% or over 13% absolute alcohol by volume. In addition to the UK and its former colonies, cider is popular in France (particularly Normandy and Brittany), Portugal (mainly in Minho and Madeira), northern Italy (specifically Friuli), and northern Spain (specifically Asturias, Basque Country). Due to their fermentation, ciders can be thought of as a fruit wine of apples, though exact definitions of either beverage can vary by culture.
Sources: en.wikipedia.org
=== 13 December === Three people were killed in an RSF drone strike on a square located near a police station in the Tayba neighbourhood of El-Obeid. Six Bangladeshi UN peacekeepers were killed in a drone strike on their base in Kadugli.
The Accreditation Commission for Health Care (ACHC) is a United States-based non-profit health care accrediting organization. It represents an alternative to the Joint Commission and CHAP, The Community Health Accreditation Program. ACHC was established in 1985 by home care health providers to create an accreditation option which was more focused on the needs of small providers. The process began in Raleigh, North Carolina, with the group incorporated in August 1986. The first accredited organization was awarded certification in January 1987. The company began offering services on a national level in 1996. Today, ACHC offers nineteen accreditation programs, nine of which are CMS approved (Acute Care Hospital, Ambulatory Surgery Center, Clinical Laboratory, Critical Access Hospital, DMEPOS, Home Health, Home Infusion Therapy, Hospice, Renal Dialysis).
Aliphatic methyl ethers cleave with difficulty and only under drastic conditions, so that these are in general only used with quinonic phenols. However, hemiacetals and acetals are much easier to cleave.
Sources: en.wikipedia.org
== Side effects == Neumega has caused allergic reaction which at times have been very serious. Symptoms have been edema of the face and tongue, or larynx; shortness of breath; wheezing; chest pain; hypotension (including shock); dysarthria; loss of consciousness, rash, urticaria, flushing, and fever. These reaction can occur after the first dose or after any later application. Neumega should be permanently discontinued in patients with any sign of allergy. Treatment is largely symptomatic. Oprelvekin also has caused quite often fluid retention, ranging from peripheral edema (approximately 40% of patients) to dyspnea and full developed lung edema with or without cardiac decompensation (see contraindications and precautions). These symptoms have led to some deaths. Fluid retention may also lead to dilutional anemia (in 10 to 15% of patients). Hypokalemia may also result. Symptoms of fluid retention have been observed more often in patients following myeloablative chemotherapy (see contraindications). Severe arrhythmias (atrial flutter and atrial fibrillation) as well as fatal cardiac arrest have also been seen which may or may be not attributed to fluid retention/increased volume. Isolated cases of stroke have been noted, those patients with previous transient ischemic attacks or partial/minor strokes may be at particular risk. Papilledema of the eyes has been observed (2%) and may lead to disturbed visual acuity and even temporary or permanent blindness. Patients with preexisting papilledema or with involvement of the central nervous system may be at higher risk.
The taste of soy sauce is predominated by saltiness, followed by moderate umami, sweetness, and finally slight bitterness, which is hard to perceive due to the masking effect of other tastes. The overall flavor of soy sauce is a result of the balance and interaction among different taste components. The saltiness is largely attributed to the presence of NaCl (common salt) in brine. The sugars hydrolyzed from starch add sweetness into soy sauce. Umami is largely caused by the presence of free amino acids, mainly glutamine and aspartic acid. Sodium from the brine and disodium ribonucleotides from the soy also add to the umami. Other amino acids cause additional basic flavors, with sweet coming from Ala, Gly, Ser, and Thr; bitter coming from Arg, His, Ile, Leu, Met, Phe, Trp, Tyr, and Val; and no taste from Cys, Lys, and Pro. The amino-acid nitrogen content, an indication of the free amino acid concentration, is used in China for grading soy sauce. The highest "special grade" is defined at ≥ 0.8 g/100 mL. Despite a large variety of volatile and odorant compounds that have been identified in soy sauce, the food product per se does not present a strong aroma. Alcohols, acids, esters, aldehydes, ketones, phenols, heterocyclic compounds, alkynes and benzenes have been identified in Chinese soy sauces. An explanation for this observation is that the aroma of soy sauce does not depend largely on the aroma-active compounds. The subtle aroma is a result of a "critical balance" achieved among all volatile and odorant compounds, whose respective concentrations are relatively low.
2,000 military advisors from the PRC and the Soviet Union trained the Việt Minh guerrilla force with the aim of turning it into a full-fledged armed force to fight off their French colonial masters and gain national independence. On top of this, the PRC sent two People's Liberation Army (PLA) artillery battalions to fight at the siege of Dien Bien Phu on May 6, 1954, with one battalion operating the Soviet Katyusha multiple-rocket launcher systems (MRLS) against French forces besieged at Dien Bien Phu's valley. From 1950 to 1954 the Chinese government shipped goods, materials, and medicine worth $54 billion (in 2025 dollars) to Vietnam. From 1950 to 1956 the Chinese government shipped 155,000 small arms, 58 million rounds of ammunition, 4,630 artillery pieces, 1,080,000 artillery shells, 840,000 hand grenades, 1,400,000 uniforms, 1,200 vehicles, 14,000 tons of food, and 26,000 tons of fuel to Vietnam. Mao Zedong considered it necessary to buttress the Viet Minh to secure his country's southern flank against potential interference by westerners, while the bulk of the PRC's regular military forces participated in the Korean War from 1950 to 1953. After the end of the Korean War and the resolution of the First Taiwan Strait Crisis, China stepped up involvement in the Indochina Wars, viewing the presence of potentially hostile forces in Indochina as the main threat.
Sources: en.wikipedia.org
MC4R is regarded as the primary mediator on the basis of binding and functional assays. Other subtypes are also engaged, which helps explain flushing and related side effects. The step from receptor activation to reported desire change remains partly inferential.
Elimination is rapid, with a half-life of a few hours. An active fragment circulates after breakdown, so biological activity may outlast measurable parent drug. This is one reason single-timepoint measurements are limited.
Because breakdown is mainly proteolytic rather than cytochrome-dependent, classic metabolic interactions are less likely. Agents affecting blood pressure could still matter. Formal interaction studies are sparse.
It primarily activates specific subtypes in the melanocortin receptor family. These receptors are G protein-coupled and mediate signaling mainly within the central nervous system.